DGIdb - ALDESLEUKIN Drug Record

ALDESLEUKIN chembl:CHEMBL1201438 ApprovedAntineoplasticImmunotherapy

Alternate Names:

HUMAN INTERLEUKIN-2
PROLEUKIN
INTERLEUKIN-2 ALDESLEUKIN
ALDESLEUKIN
INTERLEUKIN 2

Drug Info:

Drug Categories	lymphokines
Drug Categories	interleukins
Drug Class	antineoplastic agents
Year of Approval	1992
FDA Approval	approved
Drug Class	recombinant protein
Drug Indications	antineoplastic agent
Drug Categories	cytochrome p-450 cyp2e1 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs that are mainly renally excreted
Drug Categories	immunosuppressive agents
Drug Categories	increased lymphocyte activation
Drug Categories	increased lymphocyte cell production
Drug Categories	lymphocyte growth factor
Drug Categories	narrow therapeutic index drugs

(2 More Sources)

Publications:

Shibata et al., 2007, Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations., Eur. J. Haematol.
Blank et al., 2006, The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells., J. Infect. Dis.
Stauber et al., 2006, Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor., Proc. Natl. Acad. Sci. U.S.A.
Smyth et al., 2007, Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors., Blood
Fonseca et al., Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy., Scand. J. Immunol.
Lee et al., 2006, Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2., Oncol. Rep.
Steppan et al., 2006, Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog., J. Interferon Cytokine Res.
Maclennan et al., 2006, Airway inflammation in asymptomatic children with episodic wheeze., Pediatr. Pulmonol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Cornish et al., 2006, Differential regulation of T-cell growth by IL-2 and IL-15., Blood
Liu et al., 2006, [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]., Nan Fang Yi Ke Da Xue Xue Bao
Ouyang et al., 1999, Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes., Arch. Toxicol.
Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.
Waldmann, 2007, Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma., Oncogene
Waldmann, 2007, Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey., J. Clin. Immunol.
Vlad et al., 2007, Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation., Transpl. Immunol.

ALDESLEUKIN IL2RG

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

Publications:

Shibata et al., 2007, Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations., Eur. J. Haematol.

Blank et al., 2006, The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells., J. Infect. Dis.

Stauber et al., 2006, Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor., Proc. Natl. Acad. Sci. U.S.A.

ALDESLEUKIN IL2RB

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

Publications:

Lee et al., 2006, Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2., Oncol. Rep.

Steppan et al., 2006, Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog., J. Interferon Cytokine Res.

Stauber et al., 2006, Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor., Proc. Natl. Acad. Sci. U.S.A.

ALDESLEUKIN IL2RA

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Novel drug target Established target

Trial Name Proleukin IL-2

Mechanism of Interaction Interleukin-2 receptor agonist

Publications:

Liu et al., 2006, [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]., Nan Fang Yi Ke Da Xue Xue Bao

Ouyang et al., 1999, Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes., Arch. Toxicol.

Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.

ALDESLEUKIN IL2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00041

Version: 5.1.7

Alternate Names:

ALDESLEUKIN DrugBank Drug Name

110942-02-4 CAS Number

Proleukin Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Categories adjuvants, immunologic

Publications:

Waldmann, 2007, Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma., Oncogene

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.

TEND: ALDESLEUKIN
- Version: 01-August-2011
Alternate Names:

ALDESLEUKIN Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: ALDESLEUKIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class recombinant protein

FDA Approval approved

Publications:
TTD: Aldesleukin
- Version: 2020.06.01
Alternate Names:

D05PUD TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201438
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201438
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Interleukin-2 receptor agonist
Direct Interaction	yes
Trial Name	Proleukin IL-2

Novel drug target	Established target
Trial Name	Proleukin IL-2
Mechanism of Interaction	Interleukin-2 receptor agonist

ALDESLEUKIN	DrugBank Drug Name
110942-02-4	CAS Number
Proleukin	Drug Brand

Drug Type	biotech
Drug Groups	approved
Drug Categories	adjuvants, immunologic

ALDESLEUKIN Drug Record

ALDESLEUKIN chembl:CHEMBL1201438 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

ALDESLEUKIN IL2RG

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor agonist Direct Interaction yes Trial Name Proleukin IL-2

ALDESLEUKIN IL2RB

Interaction Types & Directionality: agonist (activating) modulator

Interaction Info: Mechanism of Interaction Interleukin-2 receptor agonist Direct Interaction yes Trial Name Proleukin IL-2

ALDESLEUKIN IL2RA

Interaction Types & Directionality: agonist (activating) modulator

Interaction Info: Novel drug target Established target Trial Name Proleukin IL-2 Mechanism of Interaction Interleukin-2 receptor agonist

ALDESLEUKIN IL2

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

DrugBank: DB00041

Alternate Names: ALDESLEUKIN DrugBank Drug Name 110942-02-4 CAS Number Proleukin Drug Brand

Drug Info: Drug Type biotech Drug Groups approved Drug Categories adjuvants, immunologic

TEND: ALDESLEUKIN

Alternate Names: ALDESLEUKIN Primary Drug Name

Drug Info: Year of Approval 1992 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: ALDESLEUKIN

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class recombinant protein FDA Approval approved

Publications:

TTD: Aldesleukin

Alternate Names: D05PUD TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201438

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201438

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Novel drug target Established target

Trial Name Proleukin IL-2

Mechanism of Interaction Interleukin-2 receptor agonist

Interaction Types & Directionality:

n/a

Alternate Names:

ALDESLEUKIN DrugBank Drug Name

110942-02-4 CAS Number

Proleukin Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Categories adjuvants, immunologic

Alternate Names:

ALDESLEUKIN Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class recombinant protein

FDA Approval approved

Alternate Names:

D05PUD TTD Drug ID